CCI, NextBio partner to adopt genomics in the clinic

NextBio and Cancer Care Institute (CCI) announced today a strategic partnership aimed at furthering the adoption of genomics in the clinic. The collaboration will facilitate use of the NextBio platform to interpret genomic molecular data for oncology patients and streamline the complete workflow for use of molecular data in a clinical setting.

"Cancer Care Institute cares for a very diverse group of patients of many different races and ethnicities, so we often see findings and trends that are not captured in the literature," said Morteza Dowlatshahi, M.D., Medical Director of Cancer Care Institute. "NextBio Clinical provides a powerful, easy-to-use way to interpret our patients' genomic data to conduct research studies as well as identify optimal treatments. We look forward to integrating NextBio into our daily clinical workflow."

"The ability to positively impact the treatment for a patient by understanding their individual genome and identifying actionable variants by correlating the patient's data with thousands of similar patients is truly rewarding," said Alpana Verma-Alag, M.D., Head of Clinical Development at NextBio. "Using Big Data technologies, we can now meaningfully interpret the molecular data from a person in a short amount of time, which has phenomenal implications for translational research and patient care."

"Our partnerships with Cancer Care Institute and other clinical centers complement our long-time work with pharmaceutical and biotechnology companies and research centers," said Saeid Akhtari, Co-Founder, President, and Chief Executive Officer of NextBio. "It has always been NextBio's goal to serve the full spectrum of life sciences research, from the laboratory to translational research to the clinic, thus enabling the latest advancements in genomics and other -omics research to ultimately spread to patient benefits in a seamless manner."